Polymorphism of the Human Immunodeficiency Virus Type 2 (HIV-2) Protease Gene and Selection of Drug Resistance Mutations in HIV-2-Infected Patients Treated with Protease Inhibitors

Damond, Florence; Brun‐Vézinet, Françoise; Matheron, Sophie; Peytavin, Gilles; Campa, Pauline; Pueyo, Sophie; Mammano, Fabrizio; Lastère, Stéphane; Farfara, Isabelle; Simon, François; Chêne, Geneviève; Descamps, Diane

doi:10.1128/jcm.43.1.484-487.2005

Cited by 47 publications

(44 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They altered the phenotypic susceptibility of the isolates to all the PIs tested here. These results are in keeping with data published elsewhere (2,3,9,11,13,15). Mutagenesis experiments coupled with phenotypic susceptibility testing might help to determine the impact of each substitution on PI resistance.…”

supporting

confidence: 93%

“…Peripheral blood mononuclear cell (PBMC) coculture isolates were collected from these patients before (T0, n ϭ 6) and during (T1 [time of collection of first plasma specimen during PI exposure], n ϭ 6; T2 [time of collection of second plasma specimen during PI exposure], n ϭ 2) PI exposure. Protease gene sequences of plasma and PBMC isolates were determined as previously described (3). Amino acid changes were compared with those associated with drug resistance in HIV-1 (International AIDS Society-USA [IAS-USA]).…”

mentioning

confidence: 99%

See 1 more Smart Citation

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors

Desbois

Roquebert

Peytavin

et al. 2008

Antimicrob Agents Chemother

111

View full text Add to dashboard Cite

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than against HIV-1.

show abstract

supporting

confidence: 93%

mentioning

confidence: 99%

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors

Desbois

Roquebert

Peytavin

et al. 2008

Antimicrob Agents Chemother

111

View full text Add to dashboard Cite

show abstract

“…naturally in all the HIV-2 samples sequenced (Table 2). Also, polymorphisms were found at positions L76V (M in HIV-2) and V82A/T/F (I in HIV-2), which are known to harbor major HIV-1 PI mutations, and at positions of minor mutations, E34Q (A in HIV-2), D60E (K in HIV-2), and L63P (E in HIV-2) (10,11,49).…”

Section: Resultsmentioning

confidence: 99%

Virological Response to Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency Virus Type 2 (HIV-2) and in Patients Dually Infected with HIV-1 and HIV-2 in The Gambia and Emergence of Drug-Resistant Variants

et al. 2009

View full text Add to dashboard Cite

Drug design, antiretroviral therapy (ART), and drug resistance studies have focused almost exclusively on human immunodeficiency virus type 1 (HIV-1), resulting in limited information for patients infected with HIV-2 and for those dually infected with HIV-1 and HIV-2. In this study, 20 patients, 12 infected with HIV-2 and 8 dually infected with HIV-1 and HIV-2, all treated with zidovudine (ZDV), lamivudine (3TC), and lopinavir-ritonavir (LPV/r), were followed up longitudinally for about 3 years. For 19/20 patients, viral loads were reduced to undetectable levels; the patient whose viral load remained detectable reported adverse effects associated with LPV/r that had caused him to stop taking all the drugs. HIV-2 strains containing mutations in both the protease and the reverse transcriptase gene that may confer drug resistance were observed in two patients with viral rebound, as early as 130 days (4.3 months) after the initiation of therapy. We conclude that the combination of ZDV, 3TC, and LPV/r is able to provide efficient and durable suppression of HIV-1 and HIV-2 for as long as 3 years in HIV-2-infected and dually infected patients. However, the emergence of HIV-1 and HIV-2 strains containing drug-resistant mutations can compromise the efficacy of this highly active ART.

show abstract

“…The precise detection of HIV-2 has implications for the choice of antiretroviral treatment (13). Indeed, HIV-2 strains are naturally resistant to nonnucleoside reverse transcriptase inhibitors (NNRTI) and fusion inhibitors and are less sensitive in vitro to some protease inhibitors (14,15).…”

mentioning

confidence: 99%

Clinical Evaluation of BioPlex 2200 HIV Ag-Ab, an Automated Screening Method Providing Discrete Detection of HIV-1 p24 Antigen, HIV-1 Antibody, and HIV-2 Antibody

et al. 2014

View full text Add to dashboard Cite

bEarly and accurate diagnosis is essential for optimal therapeutic outcomes in patients infected with HIV. Currently, none of the commercially available fourth-generation assays differentiate HIV-1 and HIV-2 antibodies (Ab) or the HIV-1 p24 antigen (Ag). The aim of this study was to evaluate the performance of a novel assay, the BioPlex 2200 HIV Ag-Ab. This assay uses a multiplex flow immunoassay design allowing the simultaneous detection and identification of antibodies to HIV-1 (groups M and O), HIV-2, and the HIV-1 p24 antigen, in addition to providing a traditional composite result. A total of 1,505 routine serum samples were prospectively tested. Results were compared with those from the Architect HIV Combo assay. The sensitivity of the BioPlex 2200 was 100%. The specificity assessed on repeated false-positive samples was 99.5%. In addition, 524 frozen specimens from patients known to be infected with HIV-1 or HIV-2 were tested. Of these specimens, 420 were infected with HIV-1, including 156 of known genotypes, 86 were infected with HIV-2, 7 were infected with HIV-1 and HIV-2, and 11 were from patients with acute HIV infection. Sensitivity was 100% for the HIV genotypes tested. The differentiation capabilities of the BioPlex 2200 HIV Ag-Ab assay for HIV-1, HIV-2, dual HIV-1/HIV-2, and early infections were 100%, 90.7%, 100%, and 90.9%, respectively. The BioPlex 2200 is a sensitive and specific assay that offers advantages over conventional HIV combo assays, also referred to as fourth-generation assays, to accurately differentiate and report HIV-1 p24 antigen and HIV-1 and HIV-2 antibodies.

show abstract

Polymorphism of the Human Immunodeficiency Virus Type 2 (HIV-2) Protease Gene and Selection of Drug Resistance Mutations in HIV-2-Infected Patients Treated with Protease Inhibitors

Cited by 47 publications

References 18 publications

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors

Virological Response to Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency Virus Type 2 (HIV-2) and in Patients Dually Infected with HIV-1 and HIV-2 in The Gambia and Emergence of Drug-Resistant Variants

Clinical Evaluation of BioPlex 2200 HIV Ag-Ab, an Automated Screening Method Providing Discrete Detection of HIV-1 p24 Antigen, HIV-1 Antibody, and HIV-2 Antibody

Contact Info

Product

Resources

About